Should I Buy MRKR? MRKR 2026 Analysis

Should You Buy Marker Therapeutics Inc (MRKR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.610

1 Day change

-1.23%

52 Week Range

4.070

Analysis Updated At

2026/01/26

Marker Therapeutics Inc (MRKR) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks significant positive catalysts, has weak financial performance, and no strong trading signals. While the company's pipeline shows promise, the current financials and technical indicators suggest a cautious approach.

Technical Analysis

The technical indicators are mixed. The MACD is above 0 and positively contracting, suggesting mild bullish momentum. The RSI is neutral at 62.716, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock's historical trend suggests a high probability of a decline in the next week (-0.49%) and month (-6.79%).

Options Data

Positive Catalysts

The company is advancing innovative MAR-T cell therapies, positioning itself as a potential leader in cancer immunotherapy. Analysts have a Buy rating with a $10 price target, indicating long-term growth potential.

Neutral/Negative Catalysts

The company's financial performance in Q3 2025 shows significant declines in revenue (-35.99% YoY), net income (-13.41% YoY), and EPS (-53.85% YoY). There are no recent news updates or significant insider/hedge fund trading trends to support bullish sentiment. The stock's short-term trend indicates a likely decline.

Financial Performance

In Q3 2025, the company experienced a revenue drop of -35.99% YoY, net income decline of -13.41% YoY, and EPS drop of -53.85% YoY. Despite a gross margin of 100%, the overall financial performance is weak.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright initiated a Buy rating with a $10 price target, citing the potential of the company's MAR-T cell therapies to overcome limitations in cancer immunotherapy. However, this is a long-term perspective, and the current financials do not align with immediate growth.

2 Analyst Rating

Wall Street analysts forecast MRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRKR is 9 USD with a low forecast of 8 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.630

Low

Averages

High

Current: 1.630

Low

Averages

High

H.C. Wainwright

Patrick Trucchio

Buy

initiated

$10

AI Analysis

2025-12-08

Reason

H.C. Wainwright

Patrick Trucchio

Price Target

$10

AI Analysis

2025-12-08

initiated

Buy

Reason

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Marker Therapeutics with a Buy rating and $10 price target. The company's pipeline of non-genetically engineered T cell-based immunotherapies has the potential to overcome safety, efficacy, and scalability limitations of single-antigen targeted immunotherapy modalities including chimeric antigen receptor T cells, the analyst tells investors in a research note. The firm says Marker is advancing both autologous and allogeneic MAR-T cell therapies through clinical development as part of its wholly-owned pipeline. H.C. Wainwright believes MAR-T cell therapies position Marker as an emerging leader across the "competitive" space of cancer immunotherapy.

WBB Securities

Steve Brozak

Strong Buy

Reiterates

$13

2025-04-01

Reason

WBB Securities

Steve Brozak

Price Target

$13

2025-04-01

Reiterates

Strong Buy

Reason

MRKR Should I Buy

MRKR Should I Buy

Should You Buy Marker Therapeutics Inc (MRKR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch